Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sulfasalazin (ausschl. FMR, N2), ATC M01CX02 f. d. Z. 01.11.26-31.10.28 (zzgl. V.-Option 1x12 Mon)
Germany · Hamburg · how to bid here →
Your path to submission
- Deadline: 5 September 2029 at 00:00 — 1082 days left.
- The submission point is stated in the notice (link on the right).
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- The median procedure drew 9 bids (3,222 procedures with a bid count); 7% ended with a single bidder. Sector: median 2 bids.n = 3,222
- In this sector the buyer awards roughly every month (2768 awards, most recently June 2026) — by that rhythm the next award was due around July 2026. The last award went to Sanofi-Aventis Deutschland GmbH.n = 2,768
- 82% of this buyer's awards went to companies that had already won here before (3,227 awards since 2017, spread over 567 companies). That is well above the sector norm (62%) — newcomers have a harder time here than elsewhere.n = 3,227 awards since 2017
- 83% of the bids received came from small and medium-sized enterprises (15 procedures with a bid mix). Sector: 39%.n = 15
- The award came in at a median 79% of the estimated value (6 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 6
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 13/09/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 257 contracts went to foreign companies over the last 3 years (of 21,999 recorded awards) — mostly from Austria, Netherlands, France.
Typical field: median 11 (from 4,048 awards).
What the buyer is looking for
The summary in English is being prepared. The official description below is in the original language (DE).
Show original description (DE)
§ 130a Absatz 8 SGB V ermöglicht den Krankenkassen und pharmazeutischen Unternehmen, Rahmenrabattverträge über die zu Lasten der gesetzlichen Krankenkassen abzugebenden Arzneimittel zuschließen. In Hinblick auf die dafür einschlägigen gesetzlichen Vorschriften zur Vergabe öffentlicher Aufträge, findet ein regelmäßiger Prozess wirkstoffbezogener, förmlicher Vergabeverfahren nach den Regularien des 4. Teils des GWB durch die DAK-Gesundheit statt. Für vom Bieter näher in der Anlage 2 zum Vertrag zu benennende Arzneimittel zu dem o. g. Wirkstoff Sulfasalazin (ausschließlich FMR in der Normgröße N2), ATC M01CX02, beabsichtigt die DAK-Gesundheit, bis zum Inkrafttreten neuer Arzneimittelrabattverträge mit möglichst allen interessierten pharmazeutischen Unternehmen Arzneimittelrabattverträge abzuschließen. Ein Rabattvertrag i.R.d. Zulassungsmodells zu dem o. g. Wirkstoff tritt erstmals am 01.11.2026 in Kraft und endet am 31.10.2028 (zzgl. Verlängerungsoption 1x12 Monate). Er endet unabhängig davon automatisch mit Inkrafttreten des Exklusivvertrages.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 182 | 2022–2026 |
| kohlpharma GmbH · Merzig | 165 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 131 | 2022–2026 |
| CC Pharma GmbH · Densborn | 128 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 118 | 2015–2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.
How to bid
Guide: how to apply on cosinex Vergabemarktplatz / DTVP → Registration, signature, fees — from the operator's bidder manual.